Kazia Therapeutics announced promising preclinical results for paxalisib in treating HR+/HER2- breast cancer, showing it can resensitize tumors resistant to CDK4/6 inhibitors and enhance standard therapies. The company plans to expand its ongoing TNBC trial to include a three-arm study evaluating paxalisib combined with fulvestrant and palbociclib versus standard care, aiming to enroll the first patient by the end of 2026 and complete enrollment by 2027. This expansion targets a large patient group with significant unmet needs, supported by a new provisional patent and biomarker-driven precision medicine approach. Clinical updates are expected through 2027 with full results anticipated in 2028.
Alphabet CEO Sundar Pichai revealed that the company is facing challenges in rapidly expanding its AI capacity to meet demand. Meanwhile, competitor Anthropic has successfully secured 5 gigawatts of AI computing power, highlighting a significant deve...
In August, SpaceX stock rose above its IPO price of $135 but did not surpass its first-day open or close. Leading AI platforms—Anthropic's Claude, OpenAI's ChatGPT, and Google's Gemini—forecast a moderate bullish trend for SpaceX shares by September ...
Ripple has partnered with SettleMint to integrate Ripple Custody with SettleMint’s Digital Asset Lifecycle Platform (DALP), enabling regulated financial institutions in Asia Pacific to issue, custody, and manage digital assets through a unified infra...
Bitcoin ETFs, particularly the iShares Bitcoin Trust (IBIT), attracted nearly $1 billion in inflows last week, marking the largest weekly buying since the October 2025 flash crash. This surge in institutional investment has driven Bitcoin's price up ...
Stifel analysts highlight significant growth potential at ACG Metals' Gediktepe mine in Türkiye beyond the first copper concentrate recently produced. The Enriched Ore Project, expected to complete late 2026, is already factored into their positive o...
